AQST
Price
$2.38
Change
+$0.16 (+7.21%)
Updated
May 15 closing price
Capitalization
383.26M
88 days until earnings call
ESPR
Price
$0.78
Change
+$0.05 (+6.85%)
Updated
May 15 closing price
Capitalization
495.94M
81 days until earnings call
Ad is loading...

AQST vs ESPR

Header iconAQST vs ESPR Comparison
Open Charts AQST vs ESPRBanner chart's image
Aquestive Therapeutics
Price$2.38
Change+$0.16 (+7.21%)
Volume$3.39M
Capitalization383.26M
Esperion Therapeutics
Price$0.78
Change+$0.05 (+6.85%)
Volume$9.24M
Capitalization495.94M
AQST vs ESPR Comparison Chart
Loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. ESPR commentary
May 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and ESPR is a Hold.

Ad is loading...
COMPARISON
Comparison
May 16, 2025
Stock price -- (AQST: $2.38 vs. ESPR: $0.78)
Brand notoriety: AQST and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AQST: 231% vs. ESPR: 160%
Market capitalization -- AQST: $383.26M vs. ESPR: $495.94M
AQST [@Pharmaceuticals: Other] is valued at $383.26M. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, both AQST and ESPR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 4 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 4 bullish, 5 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than AQST.

Price Growth

AQST (@Pharmaceuticals: Other) experienced а -13.77% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -12.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.55%. For the same industry, the average monthly price growth was +12.52%, and the average quarterly price growth was +28.65%.

Reported Earning Dates

AQST is expected to report earnings on Aug 12, 2025.

ESPR is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.55% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESPR($496M) has a higher market cap than AQST($383M). AQST YTD gains are higher at: -33.146 vs. ESPR (-64.673). AQST has higher annual earnings (EBITDA): 1.18M vs. ESPR (-150.11M). ESPR has more cash in the bank: 82.2M vs. AQST (23.9M). AQST has less debt than ESPR: AQST (33.3M) vs ESPR (266M). ESPR has higher revenues than AQST: ESPR (116M) vs AQST (50.6M).
AQSTESPRAQST / ESPR
Capitalization383M496M77%
EBITDA1.18M-150.11M-1%
Gain YTD-33.146-64.67351%
P/E RatioN/AN/A-
Revenue50.6M116M44%
Total Cash23.9M82.2M29%
Total Debt33.3M266M13%
FUNDAMENTALS RATINGS
AQST vs ESPR: Fundamental Ratings
AQST
ESPR
OUTLOOK RATING
1..100
157
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8996
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (35) in the Pharmaceuticals Major industry is in the same range as ESPR (36) in the Biotechnology industry. This means that AQST’s stock grew similarly to ESPR’s over the last 12 months.

AQST's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to ESPR’s over the last 12 months.

AQST's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to ESPR’s over the last 12 months.

AQST's Price Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as ESPR (96) in the Biotechnology industry. This means that AQST’s stock grew similarly to ESPR’s over the last 12 months.

AQST's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ESPR (100) in the Biotechnology industry. This means that AQST’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTESPR
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 17 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY590.462.87
+0.49%
SPDR® S&P 500® ETF
BTC.X103744.640000205.226560
+0.20%
Bitcoin cryptocurrency
GME28.63-0.10
-0.35%
GameStop Corp
AAPL211.45-0.88
-0.41%
Apple
TSLA342.82-4.86
-1.40%
Tesla

AQST and

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with OGI. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+7.21%
OGI - AQST
35%
Loosely correlated
+1.64%
SCYX - AQST
33%
Poorly correlated
+3.03%
TLRY - AQST
32%
Poorly correlated
-0.32%
ETON - AQST
32%
Poorly correlated
+15.07%
DERM - AQST
31%
Poorly correlated
+18.93%
More

ESPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ESPR has been loosely correlated with ALKS. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ESPR jumps, then ALKS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+6.47%
ALKS - ESPR
33%
Loosely correlated
+1.93%
DVAX - ESPR
30%
Poorly correlated
+1.17%
EVO - ESPR
26%
Poorly correlated
-3.43%
PAHC - ESPR
25%
Poorly correlated
+2.01%
AQST - ESPR
24%
Poorly correlated
+7.21%
More